GlassScriptPhysician profile
Randolph H Renzi
NPI 1275512550
$4,026.89
in general payments reported to CMS, 2019-2025
25 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $394 · 2021: $278 · 2022: $508 · 2023: $1,028 · 2024: $651 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,017.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $522.24 | 2023-2024 | Corevalve Evolut R, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $502.24 | 2019-2025 | |
| Pfizer INC. | $356.17 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $326.89 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.98 | 2019-2024 | Jardiance |
| Amgen INC. | $260.88 | 2019-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $247.20 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $228.82 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $201.61 | 2019-2022 | |
| Boston Scientific Corporation | $178.38 | 2020-2023 | Watchman Access System |
| Esperion Therapeutics, INC. | $168.71 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $147.41 | 2019-2024 | Lifevest |
| Abiomed | $141.80 | 2023 | Impella |
| Astrazeneca Pharmaceuticals LP | $72.38 | 2019-2021 | |
| Biotronik INC. | $64.35 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $60.71 | 2023-2024 | Ozempic, Rybelsus |
| Medtronic Vascular, INC. | $57.50 | 2019-2020 | |
| Amarin Pharma, INC. | $51.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $33.22 | 2019-2023 | |
| Recor Medical INC | $23.17 | 2025 | Paradise Ultrasound Renal Denervation System |
| Philips North America LLC | $20.02 | 2022 | |
| Lantheus Medical Imaging, INC. | $18.38 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.23 | 2019 | |
| Bridgebio Pharma, INC. | $14.85 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $14.12 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Renzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.